GlassScriptPhysician profile
Geetha Soodini
NPI 1093872558
$7,793.57
in general payments reported to CMS, 2019-2025
54 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $763 · 2021: $1,237 · 2022: $1,188 · 2023: $1,122 · 2024: $1,074 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,308 · Education: $20.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,308.20 |
| Education | $20.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $838.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $834.97 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $765.88 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $422.49 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $384.27 | 2019-2024 | Omnipod |
| Medtronic, INC. | $353.98 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Sanofi-Aventis U.S. LLC | $285.94 | 2019-2024 | |
| Mannkind Corporation | $245.07 | 2019-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $221.69 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.00 | 2020-2025 | Jardiance |
| Abbvie INC. | $206.28 | 2019-2025 | Synthroid |
| Dexcom, INC. | $198.25 | 2019-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $197.80 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Medtronic Minimed, INC. | $188.75 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $182.94 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetha Soodini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.